AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates

Core Insights - AnaptysBio, Inc. reported quarterly earnings of $0.52 per share, significantly beating the Zacks Consensus Estimate of a loss of $1.06 per share, marking an earnings surprise of +149.06% [1] - The company achieved revenues of $76.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 145.36% and showing a substantial increase from $30.02 million in the same quarter last year [2] - AnaptysBio shares have increased approximately 172.2% year-to-date, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of AnaptysBio's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $82.95 million, while for the current fiscal year, the estimate is -$3.57 on revenues of $146.17 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AnaptysBio belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Ovid Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.15 per share, reflecting a year-over-year change of +25%, with revenues anticipated to be $0.34 million, up 100% from the previous year [9]